Contineum Therapeutics (CTNM) Stock Price, News & Analysis

Company Overview

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $14.71 to $15.88
• 50-Day Range: $11.30 to $16.33
• 52-Week Range: $3.72 to $16.91
• Volume: 378,661 shs
• Average Volume: 468,650 shs
• Market Capitalization: $564.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Hold

Contineum Therapeutics Stock Analysis - MarketRank™

Contineum Therapeutics scored higher than 32% of companies evaluated by MarketBeat, and ranked 677th out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Contineum Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Contineum Therapeutics has a consensus price target of $20.00, representing about 32.5% upside from its current price of $15.10.

Amount of Analyst Coverage

Contineum Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Contineum Therapeutics are expected to decrease in the coming year, from ($1.68) to ($1.72) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Contineum Therapeutics is -7.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Contineum Therapeutics is -7.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Contineum Therapeutics has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.81% of the float of Contineum Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Contineum Therapeutics has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in Contineum Therapeutics has recently increased by 15.60%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Contineum Therapeutics does not currently pay a dividend.

Dividend Growth

Contineum Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Contineum Therapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Contineum Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Contineum Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.90% of the stock of Contineum Therapeutics is held by insiders.

Percentage Held by Institutions

Contineum Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 7/05/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CTNM
• Previous Symbol: NASDAQ:CTNM
• CIK: 1855175
• Web: www.contineum-tx.com
• Phone: (858) 333-5280
• Fax: N/A
• Employees: 31
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Contineum Therapeutics: $20.00
• High Price Target: $22.00
• Low Price Target: $16.00
• Potential Upside/Downside: +32.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$59.98 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -27.09%
• Return on Assets: -25.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 38.00
• Quick Ratio: 38.00

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.99 per share
• Price / Book: 2.16

Miscellaneous

• Outstanding Shares: 37,386,000
• Free Float: 34,433,000
• Market Cap: $564.53 million
• Optionable: N/A
• Beta: 0.70